Short Interest in Orion Oyj (OTCMKTS:ORINY) Expands By 20.0%

Orion Oyj (OTCMKTS:ORINY) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 600 shares, an increase of 20.0% from the February 13th total of 500 shares. Based on an average daily trading volume, of 700 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.0% of the company’s stock are short sold.

Orion Oyj Stock Performance

Orion Oyj stock remained flat at $29.76 during midday trading on Tuesday. The company had a trading volume of 115 shares, compared to its average volume of 3,410. The company’s fifty day moving average is $26.81 and its two-hundred day moving average is $25.49. Orion Oyj has a 1-year low of $17.50 and a 1-year high of $30.25. The stock has a market capitalization of $8.40 billion, a PE ratio of 23.62 and a beta of 0.25. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25.

Orion Oyj (OTCMKTS:ORINY) last announced its earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The business had revenue of $463.41 million for the quarter. On average, sell-side analysts anticipate that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Nordea Equity Research lowered Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.